|Brian G.M. Durie, MD|
|Born||1942 (age 77–78)|
North Berwick, Scotland
|Board member of|
Brian G.M. Durie, MD, is a Scottish hematologist famous for his research and efforts regarding multiple myeloma and blood disorders. He is the Chairman of the Board and Scientific Director for the International Myeloma Foundation and a specialist in multiple myeloma and related disorders at the Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Furthermore, Durie is known for his development of the multiple myeloma staging system.
- 1 Early Life and Education
- 2 Faculty Positions
- 3 Career and Research
- 4 Awards and Distinctions
- 5 Publications
- 6 References
- 7 Brian G.M. Durie, MD
Early Life and Education
Durie was born December 1942 in Gullane, Scotland. and graduated in 1960 from North Berwick High School. Subsequently, Durie attended the University of Edinburgh Medical School and graduated in 1966. After completing both Medical and Surgical House Officer positions at the University of Edinburgh Royal Infirmary in 1967, Durie moved to the United States to complete his Medical Residency and Subspecialty training. His training at Mayo Clinic in Minnesota was completed in 1972 and led to Specialty Board Certification in Internal Medicine (ABIM) in 1972 followed by his Certification in Hematology (ABIM) in 1974 and Oncology (ABIM) in 1975. Durie then obtained his Medical licensure in Minnesota in 1972, Arizona in 1974 and California in 1993
Upon completing Subspecialty Training, Durie joined the Medical Faculty of the University of Arizona (Tucson) in 1972 where he progressed to Full Professor status in the Section of Hematology/Oncology in 1981.. Durie served as Head of the Hematology Section and Director of the Myeloma Program. In 1989, Durie became a Professor and Head of the Department of Clinical and Laboratory Hematology at the University of London where he also established a Myeloma Program. In 1992, he returned to the United States in the Division of Hematology/Oncology at Cedars-Sinai Medical Center in Los Angeles. Upon his return to the United States, Durie stepped down from this full academic position to assume Directorship of the Hematological Research and Myeloma Programs for Aptium Oncology Inc. (subsequently AMyC Myeloma Consortium) also based at Cedars-Sinai Medical Center in the Comprehensive Cancer Center Division. Durie currently remains as a myeloma specialist physician
Career and Research
Development of A Staging System
Throughout his career, Durie has focused upon laboratory and clinical research in the area of multiple myeloma. His key research articles have focused on classifying and staging myeloma. Durie’s first faculty position at the University of Arizona was with Dr. Sydney Salmon with the assignment to develop a clinical staging system for multiple myeloma.. This was based upon a new system for directly measuring the number of myeloma cells within the body. The novel approach led to the publication of a seminal paper on Myeloma Staging in the journal Cancer in 1975, which has been cited more than 3000 times by other scientists. This publication continues to be referenced as the standard way to clinically stage multiple myeloma, named the Durie-Salmon Staging System. Durie has co-authored two updates to the staging system.
Dr. Salmon and Durie also authored a paper that concluded that the pretreatment labeling index provides helpful prognostic information in addition to tumor mass staging, which was patented. Furthermore, Durie showed it was possible to stratify myeloma patients based on combinations of serum beta 2 microglobulin with both albumin and age, producing significant separation of patients into low-, intermediate-, and high-risk categories. His research concluded that serum beta 2 microglobulin is the most powerful prognostic factor currently available for multiple myeloma. In 2006, Durie and team created an international uniform response criteria for multiple myeloma, which became very substantial for use by doctors and other researchers. Durie co-authored an update to the response criteria in 2016.
The Creation of The International Myeloma Foundation: Accelerating the search for a cure
In 1990, Durie co-created a non-profit foundation, the International Myeloma Foundation (IMF). Formed in conjunction with Brian Novis and Susie Lavitt. The Mission of the IMF is: “To improve the quality of life for myeloma patients while working towards prevention and a cure”. As reflected in the mission statement, the major goals of the organization are to educate and support myeloma patients while fundraising for research to both prevent myeloma as well as find a cure. Durie has continued to serve as both the Chairman of the Board and Scientific Director. The IMF has established myeloma patient support groups in the US and globally, created the International Myeloma Working Group (IMWG) with the top 250 myeloma experts to conduct collaborative research and guideline development, as well as establishing the Black Swan Research Initiative to conduct treatment trials to achieve a cure for myeloma.
Awards and Distinctions
Durie is the recipient of numerous honors and awards for excellence. He is a Leukemia Society of America Scholar and a U.S. Hematologic Research Foundation Annual Awardee. Durie received the 2006 Robert A. Kyle Lifetime Achievement Award, which honors a physician who most exemplifies singular dedication to and compassion for myeloma patients in the search for the best treatment for myeloma. In 2009, Durie also received the Waldenström’s Award in recognition of his contributions to the field of multiple myeloma research. Furthermore, Durie were awarded an Honorary Doctorate of Medicine from the Vrije Universiteit Brussel (VUB) in 2019.
1991 5th Annual Hematological Research Award
2002 Nuclear Medicine First Prize Award
2006 Robert A. Kyle Lifetime Achievement Award
2009 Waldenström Award for Myeloma Research
2010 Philadelphia Humanitarian Award
2011 Joseph Michaeli Award for Contributions to Myeloma Research
2014 Mayo Distinguished Alumni Award
2018 Top Publisher Award
2019 Honorary Doctorate of Medicine: Free University of Brussels
Durie has published original scientific manuscripts in all of the major journals focused on hematologic malignancies including: Blood, JCO, BJH, Lancet Oncology, Cancer, Cancer Research and Leukemia, as well as broader scientific journals such as NEJM, Lancet, Science, Nature and JAMA. Durie has also written over 600 research papers, sixteen book chapters, and five books. In 2018, Durie was listed among “Highly cited Researchers 2018” in the category of clinical medicine
- "Brian G.M. Durie, MD - Curriculum Vitae". International Myeloma Foundation. Retrieved 2019-09-20.
- "CURRICULUM VITAE Brian GM Durie, MD". studylib.net. Retrieved 2019-09-20.
- "Brian G. M. Durie, MD". www.cedars-sinai.edu. Retrieved 2019-09-20.
- "Criterium's Proven Formula for Clinical Trial Success". www.criteriuminc.com. Retrieved 2019-09-20.
- "History". University of Arizona Cancer Center. 2018-11-27. Retrieved 2019-09-20.
- Durie, Brian G. M.; Salmon, Sydney E. (1975). <842::aid-cncr2820360303>3.0.co;2-u "A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival". Cancer. 36 (3): 842–854. doi:10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. ISSN 0008-543X.
- Durie, B.; Salmon, S. (1975-12-12). "High speed scintillation autoradiography". Science. 190 (4219): 1093–1095. doi:10.1126/science.1188385. ISSN 0036-8075.
- Allen, George (2007). "Cell saver blood transfusions; colorectal surgery antibiotic prophylaxis; preoperative clinics; colonoscopy failure rates". AORN Journal. 85 (4): 823–830. doi:10.1016/s0001-2092(07)60158-6. ISSN 0001-2092.
- on behalf of the International Myeloma Working Group; Durie, B G M; Harousseau, J-L; Miguel, J S; Bladé, J; Barlogie, B; Anderson, K; Gertz, M; Dimopoulos, M (2006). "International uniform response criteria for multiple myeloma". Leukemia. 20 (9): 1467–1473. doi:10.1038/sj.leu.2404284. ISSN 0887-6924.
- Palumbo, Antonio; Avet-Loiseau, Hervé; Oliva, Stefania; Lokhorst, Henk M.; Goldschmidt, Hartmut; Rosinol, Laura; Richardson, Paul; Caltagirone, Simona; Lahuerta, Juan José (2015-09-10). "Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group". Journal of Clinical Oncology. 33 (26): 2863–2869. doi:10.1200/JCO.2015.61.2267. ISSN 0732-183X. PMC 4846284. PMID 26240224.
- "Media Kit". International Myeloma Foundation. Retrieved 2019-09-20.
- "International Myeloma Working Group". International Myeloma Foundation. Retrieved 2019-09-20.
- "Black Swan Research Initiative". International Myeloma Foundation. Retrieved 2019-09-20.
- "Kyle Lifetime Achievement Award". International Myeloma Foundation. Retrieved 2019-09-20.
- "Dr. Brian Durie Receives the Prestigious Waldenström's Award in Recognition of His Many Contributions to the Field of Multiple Myeloma". www.businesswire.com. 2009-02-27. Retrieved 2019-09-20.
- "Brian G.M. Durie, M.D. (I, '70, HEM, '72) Receives 2014 Mayo Distinguished Alumni Award". Mayo Clinic Alumni Association. Retrieved 2019-09-20.
- "Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award". www.businesswire.com. 2014-10-22. Retrieved 2019-09-20.
- "International Myeloma Foundation (IMF) Co-Founders Susie Durie and Brian Durie, MD, Receive a Joint Honorary Doctorate in Recognition of Scientific Excellence". International Myeloma Foundation. Retrieved 2019-09-20.
- "Highly Cited Researchers - The Most Influential Scientific Minds". HCR. Retrieved 2019-09-20.
Brian G.M. Durie, MD
This article "Brian Durie" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Brian Durie. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.